



1635  
7c  
\$

ATTORNEY'S DOCKET NO: C1037/7017 (HCL/MAT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert L. Bratzler and Deanna M. Petersen  
Serial No: 09/800,266  
Conf. No: 3753  
Filed: March 5, 2001  
For: IMMUNOSTIMULATORY NUCLEIC ACIDS AND CANCER  
MEDICAMENT COMBINATION THERAPY FOR THE TREATMENT  
OF CANCER  
Examiner: Jon E. Angell  
Art Unit: 1635

COPY OF PAPERS  
ORIGINALLY FILED


RECEIVED

JUN 11 2002

TECH CENTER 1600/2900

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on May 22, 2002.

  
Maria A. Trevisan, Reg. No. 48,207

Commissioner for Patents  
Washington, D.C. 20231

**TRANSMITTAL**

Transmitted herewith are the following documents:

- ☒ Response to Restriction Requirement
- ☒ Check in the amount of \$110.00 (one month extension, large entity)
- ☒ Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

If any additional fee is determined to be due by the Examiner, the Examiner is authorized to charged the appropriate fee to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully Submitted,



Maria A. Trevisan, Reg. No. 48,207  
Wolf, Greenfield & Sacks, P.C.  
Federal Reserve Plaza, 600 Atlantic Avenue  
Boston, MA 02210-2211  
Attorney for Applicants

Docket No. C1037/7017 (HCL/MAT)  
Date: May 22, 2002  
X06/09/02



COPIES OF PAPERS  
ORIGINALLY FILED

#9  
KP  
6-18-02

ATTORNEY'S DOCKET NO: C1037/7017 (HCL/MAT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert L. Bratzler and Deanna M. Petersen  
Serial No: 09/800,266  
Conf. No: 3753  
Filed: March 5, 2001  
For: IMMUNOSTIMULATORY NUCLEIC ACIDS AND CANCER  
MEDICAMENT COMBINATION THERAPY FOR THE TREATMENT  
OF CANCER  
Examiner: Jon E. Angell  
Art Unit: 1635


RECEIVED

JUN 11 2002

TECH CENTER 1600/2900

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on May 22, 2002.

  
Maria A. Trevisan, Reg. No. 48,207

Commissioner for Patents  
Washington, D.C. 20231

**Response to Restriction Requirement**

Sir:

In response to the Restriction Requirement mailed from the United States Patent and Trademark Office on April 9, 2002, Applicants hereby request entry of the following election. A one month extension of time is respectfully requested and the appropriate fee is submitted herewith.

**Election**

Applicants hereby elect Group I (claims 1-17 and 31).

Applicants further elect

- a) a chemotherapeutic agent that is Paxex/Paclitaxel;
- b) an immunotherapeutic agent that is Herceptin;
- c) a cancer vaccine that is Her2/neu; and
- d) a hormone therapy that is estrogens.

Applicants wish to clarify that Group I drawn to a method of cancer treatment/prevention using a nucleic acid embraces claims 1-17 and 31. The Examiner listed claims 1-12 and 31 and omitted claims

615062.1

06/10/2002 MBERHE 00000035 09800266

01 FC:115

110.00 DP